Sacubitril/valsartan (Entresto®)

Assessment Status Assessment Process Complete
Drug Sacubitril/valsartan
Brand Entresto®
Indication For the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.
Assessment Process
Rapid review commissioned 06/11/2015
Rapid review completed 30/11/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 07/03/2016
NCPE assessment completed 08/07/2016
NCPE assessment outcome Reimbursement Recommended

The NCPE considers valsartan/sacubitril (Entresto) cost-effective for the current licensed indication and recommends reimbursement.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.